Sharon F Terry

Ms. Sharon F Terry

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2017 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SDSafiyya Dharssi
Safiyya Dharssi
DWDurhane Wong-Rieger
Durhane Wong-Rieger
MHMatthew Harold
Matthew Harold
STSharon F Terry
Sharon F Terry
Rare diseases collectively exert a global public health burden in the severity of their manifestations and the total number of people they afflict. For many patients, considerable barriers exist in terms of access to appropriate care, delayed diagnosis and limited or non-existing treatment options. Motivated by these challenges, the rare disease patient community has played a critical role, elevating the patient voice and mobilizing legislation to support the development of programs that address the needs of patients with rare diseases. The US Orphan Drug Act of 1983 served as a key milestone in this journey, providing a roadmap for other countries to introduce and implement similar orphan drug legislation; more recently, the European Union (EU) has gone further to encourage the widespread adoption and implementation of rare disease plans or strategies designed to more adequately address the comprehensive needs of patients with rare diseases. Despite these legislative efforts and the growing contributions of patient advocacy groups in moving forward implementation and adoption of rare disease programs, gaps still exist across the policy landscape for several countries. To gain deeper insights into the challenges and opportunities to address key needs of rare disease patients, it is critical to define the current status of rare disease legislation and policy across a geographically and economically diverse selection of countries. We analyzed the rare disease policy landscape across 11 countries: Germany, France, the United Kingdom, Canada, Bulgaria, Turkey, Argentina, Mexico, Brazil, China, and Taiwan. The status and implementation of policy was evaluated for each country in the context of key patient needs across 5 dimensions: improving coordination of care, diagnostic resources, access to treatments, patient awareness and support, and promoting innovative research. Our findings highlight the continuing role of the patient community in driving the establishment and adoption of legislation and programs to improve rare disease care. Further, we found that while national rare disease plans provide important guidance for improving care, implementation of plans is uneven across countries. More research is needed to demonstrate the effect of specific elements of rare disease plans on patient outcomes.

1 February 2007 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
STSharon F Terry
Sharon F Terry
PTPatrick F. Terry
Patrick F. Terry
KRKatherine A. Rauen
Katherine A. Rauen
JUJouni Uitto
Jouni Uitto
LBLionel G. Bercovitch
Lionel G. Bercovitch

7 January 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KOKieran C. O’dOherty
Kieran C. O’dOherty
MSMahsa Shabani
Mahsa Shabani
EDEdward S. Dove
Edward S. Dove
HBHeidi Beate Bentzen
Heidi Beate Bentzen
PBPascal Borry
Pascal Borry
WBWylie Burke
Wylie Burke

1 March 2015 in Genetic Testing and Molecular Biomarkers
Verified
Journal Article
Closed access
STSharon F Terry
Sharon F Terry

7 March 2018 in Human Genomics
Verified
Journal Article
Open access
PDF file
JKJane Kaye
Jane Kaye
STSharon F Terry
Sharon F Terry
EJEric Juengst
Eric Juengst
SCSarah Coy
Sarah Coy
JHJennifer R. Harris
Jennifer R. Harris
ACAnne Cambon-Thomsen
Anne Cambon-Thomsen
Governments, funding bodies, institutions, and publishers have developed a number of strategies to encourage researchers to facilitate access to datasets. The rationale behind this approach is that this will bring a number of benefits and enable advances in healthcare and medicine by allowing the maximum returns from the investment in research, as well as reducing waste and promoting transparency. As this approach gains momentum, these data-sharing practices have implications for many kinds of research as they become standard practice across the world. The governance frameworks that have been developed to support biomedical research are not well equipped to deal with the complexities of international data sharing. This system is nationally based and is dependent upon expert committees for oversight and compliance, which has often led to piece-meal decision-making. This system tends to perpetuate inequalities by obscuring the contributions and the important role of different data providers along the data stream, whether they be low- or middle-income country researchers, patients, research participants, groups, or communities. As research and data-sharing activities are largely publicly funded, there is a strong moral argument for including the people who provide the data in decision-making and to develop governance systems for their continued participation. We recommend that governance of science becomes more transparent, representative, and responsive to the voices of many constituencies by conducting public consultations about data-sharing addressing issues of access and use; including all data providers in decision-making about the use and sharing of data along the whole of the data stream; and using digital technologies to encourage accessibility, transparency, and accountability. We anticipate that this approach could enhance the legitimacy of the research process, generate insights that may otherwise be overlooked or ignored, and help to bring valuable perspectives into the decision-making around international data sharing.

18 September 2001 in American Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
STSharon F Terry
Sharon F Terry
CBCharles D. Boyd
Charles D. Boyd